Hyperbaric oxygen therapy for COVID pneumonia
- Funded by
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Principal Investigator
Dr. Sylvain BoetResearch Location
CanadaLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
When COVID-19 takes over the lungs, it can feel like you can't get enough air into your body, no matter how much you gasp. When this kind of COVID pneumonia sets in, the only option is to hook the patient up to an artificial breathing machine (a ventilator), with a tube down the throat (intubation). Unfortunately, only half of people with COVID-19 who require intubation will survive after this invasive, last-resort treatment. Dr. Sylvain Boet and his colleagues believe that hyperbaric oxygen therapy (HBOT) may be able to help some people with COVID-19 pneumonia avoid mechanical ventilation and increase survival. HBOT involves placing patients in a pressurized room or chamber so they can breathe 100% oxygen. It can increase the delivery of oxygen to tissues by 10 to 20-fold and can also boost the immune system and help the body fight infections. Small studies in other countries suggest that HBOT may help treat patients with COVID-19 pneumonia, but more research is needed. Dr. Boet and his team will initiate a study of HBOT in people with COVID-19 pneumonia at The Ottawa Hospital, and will work with colleagues around the world to explore the possibility of expanding the trial to other hospitals.